Please login to the form below

Not currently logged in
Email:
Password:

ADA

This page shows the latest ADA news and features for those working in and with pharma, biotech and healthcare.

Lilly showcases tirzepatide type 2 diabetes data at ADA 2021

Lilly showcases tirzepatide type 2 diabetes data at ADA 2021

Eli Lilly has showcased new positive data for its investigational type 2 diabetes drug tirzepatide at Annual Scientific Sessions of the American Diabetes Association (ADA).

Latest news

More from news
Approximately 19 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    Despite their limitations, available outcome scales, such as the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), are sufficiently sensitive to capture clinically meaningful changes.

  • Assessing the risks in annuity pricing models Assessing the risks in annuity pricing models

    GlaxoSmithKline (GSK) launched its gene therapy STRIMVELIS, a one dose treatment for severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), in Europe in 2016 with an outcomes-based annuity

  • The fight for affordable insulin The fight for affordable insulin

    The movement is also distancing itself from some of the big type 1 diabetes advocacy organisations, such as the American Diabetes Association (ADA) and the Juvenile Diabetes Foundation (JDF), which it

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    Ada is an artificial intelligence (AI) app that helps patients navigate quickly and accurately to the right health service and, ultimately, the right diagnosis. ... So far, Ada has performed eight million assessments around the globe, and every three

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    GSK’s Strimvelis for ADA-SCID (Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency) followed in 2016, and was a similar commercial failure.

More from intelligence
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Weekly industry appointments Weekly industry appointments

    There, he is medicines development leader for adenosine deaminase deficiency (ADA-SCID) gene therapy Strimvelis – the first alternative medicine to stem cell transplant for the disease that’s bagged a regulatory

  • Orchard Therapeutics appoints Mark Rothera as CEO Orchard Therapeutics appoints Mark Rothera as CEO

    The clinical data we’ve seen to date with Orchard’s therapy for ADA-SCID is exceptional, and the company has assembled and impressive R&D pipeline to apply the approach

  • Cello Health boosts senior leadership team Cello Health boosts senior leadership team

    He previously served as managing director at Medicom International, an international healthcare publishing firm as well as ADA holdings and ICI Pharmaceuticals.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
ahair@onyxhealth.com

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....